Drugs Made In America Acquisition DMIIR
NASDAQ DMIIR
$0.07 -0.01 (-7.04%)
As of: Sep 2, 2026 · 12:48 PM EDT

Drugs Made In America Acquisition (DMIIR) Operating Income (2025 - 2026)

Drugs Made In America Acquisition (DMIIR) posted quarterly Operating Income of -$235472.0 for Q4 2025, down 51.42% quarter-over-quarter from -$155513.0 in Q3 2025.

Analysis

Drugs Made In America Acquisition (DMIIR) Operating Income (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has reported Operating Income for 1 consecutive years, with -$235472.0 the latest figure, recorded in Q4 2025.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Cluster Group Holdings 8.00 Bn 8.00 Bn - -8,222.00
2 Agriculture & Natural Solutions Acquisition 853.42 Mn 853.17 Mn - -
3 K&F Growth Acquisition 836.15 Mn 836.15 Mn - -194,811.00
4 Armada Acquisition 666.54 Mn 666.49 Mn - -503,862.00
5 Pioneer Acquisition I 652.74 Mn 652.27 Mn - -177,258.00
6 Oxley Bridge Acquisition 652.11 Mn 652.11 Mn - -162,277.00
7 Titan Acquisition 651.43 Mn 941.85 Mn - -481,615.00
8 GSR IV Acquisition 622.22 Mn 622.22 Mn - -324,751.00
9 Launch One Acquisition 618.70 Mn 618.70 Mn - -593,448.00
10 Drugs Made In America Acquisition 5.10 Mn 5.10 Mn - -112,227.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -112,227.00
Dec 31, 2025 -235,472.00
Sep 30, 2025 -155,513.00